Microbot Medical MBOT
- Market cap
- $65.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −27.4%
Microbot Medical's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $105K | $241K | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $103K | $884K |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $2K | −$643K |
| R&D | $1.6M−18% | $1.1M−40% | $1.2M−28% | $1.4M+4% | $2.1M+28% | $2M+76% | $1.5M+25% | $2.1M+49% | $1.2M−43% | $1.5M−22% | $1.3M−11% | $1.9M−12% |
| SG&A | $932K−39% | $938K−21% | $1.2M−7% | $1.1M+14% | $1.2M+33% | $1.4M+54% | $1.6M+29% | $1.6M+47% | $2.7M+117% | $2.6M+80% | $3M+94% | $3.7M+129% |
| −$2.5M−27% | −$2.1M−33% | −$2.4M−18% | −$2.5M+8% | −$3.3M+30% | −$3.4M+66% | −$3M+27% | −$3.7M+48% | −$3.9M+17% | −$4.1M+21% | −$4.3M+43% | −$6.2M+66% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$2.4M−30% | −$3.2M+5% | −$2.4M−17% | −$2.5M+8% | −$3.2M+31% | −$3.4M+8% | −$2.6M+10% | −$3.5M+42% | −$3.6M+11% | −$3.5M+2% | −$3.7M+41% | −$5.6M+61% |
| −$0.21−57% | −$0.27−31% | −$0.17−53% | −$0.17−32% | −$0.20−5% | −$0.20−26% | −$0.08−53% | −$0.10−41% | −$0.07−65% | −$0.05−75% | −$0.05−38% | −$0.08−20% | |
| 11.7M+65% | 11.8M+53% | 14.1M+75% | 14.8M+61% | 16.5M+41% | 17.2M+45% | 31.1M+121% | 36.5M+146% | 48.1M+192% | 67.1M+290% | 67.2M+116% | 67.2M+84% |
EPS, diluted: 15 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY16 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Microbot Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MBOTMicrobot Medical | $65.4M | n/m | 2.4× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| Peer median | $236.3M | 21.9× | 20.9× | 1.6× | +5% | 7.1% |
More on Microbot Medical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .